

(Formerly known as, Sotac Pharmaceuticals Private Limited)

Registered Office :

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GIDC - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451

Date: August 11, 2023

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra East, Mumbai-400051

Dear Sir,

Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)

Sub: Statement of Deviation / Variation in Utilisation of Funds Raised through Public Issue, for the Quarter Ended June 30, 2023.

Name of Listed Entity	Sotac Pharmaceuticals Limited
Mode of Fund Raising	Public Issue-IPO
Date of Raising Funds	April 10, 2023 (Trading Approval Dated April 12, 2023 received from NSE) (Allotment Made on April 10, 2023)
Amount Raised (in Rs. Crores)	Fresh Issue: Rs. 33.3 Crore i.e. (3000000 Equity shares at a cash price of Rs. 111 per equity Shares (Including a Share Premium of Rs. 101/- Per Equity Share)
Report filed for Quarter/ Half year ended	June 30, 2023.
Monitoring Agency	Not Applicable
Monitoring Agency Name, if Applicable	Not Applicable
Is there a Deviation/Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of Shareholder Approval	Not Applicable
Explanation for the Deviation/Variation	Not Applicable
Comments of the Audit Committee after review	The Proceeds from IPO utilized for the Objects for which it was raised
Comments of the auditors, if any	No Comments



(Formerly known as, Sotac Pharmaceuticals Private Limited)

Registered Office :

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GIDC - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451

Objects for which funds have been raised and where there has been a deviation, in the following table;

Original Object	Modified Object, if any	Original Allocation	Modified Allocation, if any	Funds Utilised till June 30, 2023.	Amount of Deviation /Variation for quarter according to applicable object	Remarks, if any
1.To Meet Incremental Working Capital Requirements	Not Applicable	Rs.33.3 Crore	Not Applicable	1.To Meet Incremental Working Capital Requirements- Rs. 1,080.00	-	Not Applicable
2. Investment in Subsidiary				2. Investment in Subsidiary- Rs. 700.00		
3. Upgradation / Construction of Existing/New Building in the Existing Premises				3. Upgradation / Construction of Existing/New Building in the Existing Premises-Rs. 590.01		
4. General Corporate Purpose.				4. General Corporate Purpose. Rs. 739.99		
5. Public Issue Expenses				5. Public Issue Expenses Rs. 220.00		
Deviation or variation could mean:						
(a) Deviation in the objects or purpose for which the funds have been raised or						
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or						
(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.						

Kindly take the same on your record and oblige us.

Thanking you.

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad

